Full interview with Eli Lilly CEO David Ricks on positive Covid-19 treatment data

Eli Lilly said on Monday its rheumatoid arthritis drug baricitinib shortened the time taken to recover from Covid-19 in hospitalized patients when taken in combination with Gilead Sciences' antiviral remdesivir. Eli Lilly CEO David Ricks joined "Squawk Box" to discuss the trial results.